Researchers Solve Multiple Sclerosis Puzzle
News May 18, 2015
Evidence has long suggested multiple sclerosis (MS) is an autoimmune disease, but researchers have been puzzled because they found the same T cells that attack the myelin sheathing around nerve cells in MS patients are present in healthy subjects as well.
Now researchers from the Yale School of Medicine and colleagues at the Massachusetts Institute of Technology (MIT) report that auto-reactive T cells in MS patients produce different types of inflammatory hormones called cytokines than they do in healthy subjects.
“In most people, these T cells are acting to repair tissue, but in MS patients, they do damage to the nervous system,” said Dr. David Hafler, the William S. and Lois Stiles Edgerly Professor of Neurology and senior author of the study, published May 14 in the journal Science Translational Medicine.
The Yale-led team analyzed T cell populations from 23 MS patients and 22 healthy controls. Existing drugs target the MS-specific cytokines identified in the study and should be a promising new treatment for the disease, the authors say.
Hafler also noted that the same sort of process might be found in other autoimmune diseases, such as rheumatoid arthritis and Type 1 diabetes.
Yonghao Cao of Yale and Brittany A. Goods of MIT are co-first authors of the paper.
The research was funded by the National Institutes of Health and the National Multiple Sclerosis Society.
Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UKNews
Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK. Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments.READ MORE
Latent HIV Reservoirs Inherently Resistant to Elimination by CD8+ T-cellsNews
The latest “kick-and-kill” research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study found that latent HIV reservoirs show resistance to CD8+ T-cells, a type of white blood cell whose primary function is to kill infected cells.READ MORE
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE